I really suggest you read company filings. This is from the quarterly report filed Monday:
"9. SUBSEQUENT EVENTS
On October 11 2023, the Company filed a new Reg A for the marketing of 250,000,000 common shares at a price range of $0.001 to $0.003, to be determined after qualifying. This new Reg A is to provide additional funding for the marketing for BioAdaptives itself, and also for its wholly owned subsidiary, LiveStock Impact Inc, The Company is looking to expand its range of targeted human health supplements. It is also focused on the marketing effort of LiveStock Impact, Inc and its wholesale activities as well as its interest in botanical drugs. Towards this end, since October, the Company has been working with a professional entity on its press releases and marketing promotions. It expects to intensify its marketing outreach in the next two quarters. The Company also announced its launching of a new Lung Health supplement, Lung Fortress, a robust all natural supplement designed to foster Pulmonary Health."
This is where reading compression is very important. If the SEC had qualified the offering already, the company would have reported the offering is qualified. In the very real world, zero shares have been sold yet. The company will issue another public filing when the 250m shares are qualified for sale.
Facts are very important. Good luck out there.
News 
Market Data 
Discover 
